* Q2 beat with activity picking up * Pre-tax profit up by 13-16% for 2026-27e * 2025e-27e EV/EBIT of...
* '25e-'27e sales cut by 6-1% * Market softness persists, delaying customer decisions * Cost-cutting...
Redeye provides a research update following the Q2 report published by Isofol earlier today.
Redeye provides an initial take following the release of Corline’s Q2 2025 report.
Redeye comments on Gentoo Media’s Q2-results which were lower than expected and the company has trim...
Solwers reported its results for Q2 with sales of EUR 21.
Acuvi redovisade ökad nettoomsättning och EBIT i det andra kvartalet.
Redeye comments on Episurf’s rights issue of Units, which was oversubscribed to approximately 162.
Redeye comments on Elicera reporting data from cohort 2 in the ongoing CARMA study.
Nettoomsättningen för det andra kvartalet uppgick till 6,6 MEURO (10,2), vilket motsvarade en minskn...
Redeye reviews the case for IDL Diagnostics, and while we down our medium-term sales forecasts, we r...
Egetis has rapidly transferred all but one German patient, supporting the launch and indicating posi...
Cantargia’s Q2 report covers one of the most eventful periods in the company’s history.
Redeye provides an update following CLS’s Q2 2025 report.
Redeye updates its estimates and valuation following Navigo’s Q2 2025 report.
